Mycapssa (octreotide)
- Region
- 🇪🇺 EU
- Active substance
- octreotide
- Company
- Amryt Pharmaceuticals DAC
- Status
- Withdrawn
- Therapeutic area
- Acromegaly
- CHMP opinion
- Thu 15 Sep 2022
- EU approval
- Fri 02 Dec 2022
- Application
- EMEA/H/C/005826
- ATC
- H01CB02
- Official record
- www.ema.europa.eu
Indication
Mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Oczyesa Authorised · Camurus AB
Follow Mycapssa
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.